1. D.Miyazawa. hypothesis that acute hepatitis of unknown origin in children is caused by adeno-associated virus 2.https://www.bmj.com/content/377/bmj.o1067/rr-4

2. High-dose AAV gene therapy deaths. Nat Biotechnol 38, 910 (2020).https://doi.org/10.1038/s41587-020-0642-9

3. Pipe S, Leebeek FWG, Ferreira V, et al. Clinical Considerations for Capsid Choice in the Development of Liver-Targeted AAV-Based Gene Transfer. Mol Ther Methods Clin Dev . 2019;15:170-178. Published 2019 Sep 10. doi:10.1016/j.omtm.2019.08.015

4. Brodin P, Arditi M. Severe acute hepatitis in children: investigate SARS-CoV-2 superantigens. Lancet Gastroenterol Hepatol. 2022, ISSN 2468-1253,

5. Keeler AM, Flotte TR. Recombinant Adeno-Associated Virus Gene Therapy in Light of Luxturna (and Zolgensma and Glybera): Where Are We, and How Did We Get Here?. Annu Rev Virol. 2019;6(1):601-621. doi:10.1146/annurev-virology-092818-015530

6. Mingozzi F, High KA. Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood . 2013;122(1):23-36. doi:10.1182/blood-2013-01-306647

7. Hösel M, Broxtermann M, Janicki H, et al. Toll-like receptor 2-mediated innate immune response in human nonparenchymal liver cells toward adeno-associated viral vectors. Hepatology . 2012;55(1):287-297. doi:10.1002/hep.24625

8.Gao GP, Alvira MR, Wang L, Calcedo R, Johnston J, Wilson JM. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A. 2002;99(18):11854-11859. doi:10.1073/pnas.182412299

9. Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response [published correction appears in Nat Med. 2006 May;12(5):592. Rasko, John [corrected to Rasko, John JE]; Rustagi, Pradip K [added]]. Nat Med . 2006;12(3):342-347. doi:10.1038/nm1358

10. Boutin S, Monteilhet V, Veron P, et al. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Ther . 2010;21(6):704-712. doi:10.1089/hum.2009.182

11. Martino AT, Suzuki M, Markusic DM, et al. The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver. Blood . 2011;117(24):6459-6468. doi:10.1182/blood-2010-10-314518

12. Zaiss AK, Cotter MJ, White LR, et al. Complement is an essential component of the immune response to adeno-associated virus vectors. J Virol . 2008;82(6):2727-2740. doi:10.1128/JVI.01990-07

13. Afzali B, Noris M, Lambrecht BN, Kemper C. The state of complement in COVID-19. Nat Rev Immunol . 2022;22(2):77-84. doi:10.1038/s41577-021-00665-1